Lodestone Biomedical Inc.
Immediate detection of immune response from the tumor microenvironment to accelerate cancer research
Immediate detection of immune response from the tumor microenvironment to accelerate cancer research
Lodestone Biomedical Inc. is a biotechnology startup founded in 2015 and headquartered in the United States. The company's mission is to enable the immediate detection of immune response from the tumor microenvironment to accelerate cancer research. With its biosensor and reader technology, Lodestone offers a platform for a broad spectrum of longitudinal in vivo assays in the tumor microenvironment. The small-animal system and in vivo assay technology provided by Lodestone are designed to expedite cancer research efforts. It's worth noting that Lodestone's products are designed for research use only.
Although specific details about the last investment and the involved investors are not available, it is evident that Lodestone has received non-equity assistance investment on 20 May 2015. This investment likely played a crucial role in the company's early development and product commercialization.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | - | 20 May 2015 |
No recent news or press coverage available for Lodestone Biomedical Inc..
We care about your data, and we'd love to use cookies make your experience better.
